These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Baseline clinical measures and early response predict success in verteporfin photodynamic therapy for neovascular age-related macular degeneration. García-Fiñana M; Murjaneh S; Mahmood S; Harding SP Eye (Lond); 2010 Jul; 24(7):1213-9. PubMed ID: 20075972 [TBL] [Abstract][Full Text] [Related]
4. Full macular translocation (FMT) versus photodynamic therapy (PDT) with verteporfin in the treatment of neovascular age-related macular degeneration: 2-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). Lüke M; Ziemssen F; Völker M; Altpeter E; Beutel J; Besch D; Bartz-Schmidt KU; Gelisken F Graefes Arch Clin Exp Ophthalmol; 2009 Jun; 247(6):745-54. PubMed ID: 19214552 [TBL] [Abstract][Full Text] [Related]
5. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Chan WM; Lai TY; Wong AL; Tong JP; Liu DT; Lam DS Br J Ophthalmol; 2006 Mar; 90(3):337-41. PubMed ID: 16488958 [TBL] [Abstract][Full Text] [Related]
6. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441 [TBL] [Abstract][Full Text] [Related]
7. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834 [TBL] [Abstract][Full Text] [Related]
8. Combination photodynamic therapy and intravitreal ranibizumab in neovascular age-related macular degeneration in a North Indian population: a pilot study. Kumar A; Gopalakrishnan K; Sinha S Retina; 2008 Oct; 28(9):1296-301. PubMed ID: 18667951 [TBL] [Abstract][Full Text] [Related]
9. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. Chaudhary V; Mao A; Hooper PL; Sheidow TG Ophthalmology; 2007 Dec; 114(12):2183-9. PubMed ID: 18054638 [TBL] [Abstract][Full Text] [Related]
11. A prospective randomised study on low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration. Odergren A; Algvere PV; Seregard S; Kvanta A Br J Ophthalmol; 2008 Jun; 92(6):757-61. PubMed ID: 18356266 [TBL] [Abstract][Full Text] [Related]
12. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T; Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696 [TBL] [Abstract][Full Text] [Related]
13. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Lazic R; Gabric N Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776 [TBL] [Abstract][Full Text] [Related]
14. Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation--'beyond the TAP study'. Barnes RM; Gee L; Taylor S; Briggs MC; Harding SP Eye (Lond); 2004 Aug; 18(8):809-13. PubMed ID: 14963483 [TBL] [Abstract][Full Text] [Related]
15. [Photodynamic therapy with verteporfin in occult choroidal neovascularization in age-related macular degeneration]. Kürzinger GR; Stender B; Lang GK; Lang GE Klin Monbl Augenheilkd; 2010 Jun; 227(6):501-6. PubMed ID: 20349399 [TBL] [Abstract][Full Text] [Related]
16. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Azab M; Boyer DS; Bressler NM; Bressler SB; Cihelkova I; Hao Y; Immonen I; Lim JI; Menchini U; Naor J; Potter MJ; Reaves A; Rosenfeld PJ; Slakter JS; Soucek P; Strong HA; Wenkstern A; Su XY; Yang YC; Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216 [TBL] [Abstract][Full Text] [Related]
17. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Bressler NM; Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980 [TBL] [Abstract][Full Text] [Related]
18. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Heier JS; Boyer DS; Ciulla TA; Ferrone PJ; Jumper JM; Gentile RC; Kotlovker D; Chung CY; Kim RY; Arch Ophthalmol; 2006 Nov; 124(11):1532-42. PubMed ID: 17101999 [TBL] [Abstract][Full Text] [Related]
19. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Augustin AJ; Schmidt-Erfurth U Ophthalmology; 2006 Jan; 113(1):14-22. PubMed ID: 16360209 [TBL] [Abstract][Full Text] [Related]
20. Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks: one-year results of a prospective case series. Browning AC; Chung AK; Ghanchi F; Harding SP; Musadiq M; Talks SJ; Yang YC; Amoaku WM; Ophthalmology; 2005 Jul; 112(7):1227-31. PubMed ID: 15921757 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]